A study found a pneumococcal vaccine Prevenar 13 could lower the risk related to COVID-19.

The Kaiser Permanente Southern California (KPSC) has recently presented the study result of the effect of Prevenar 13 (PCV13) on elderly patients’ COVID-19 infection progress. The study was published in the Journal of Infectious Diseases.

The study has shown that in a cohort of U.S. adults aged 65 and older, PCV13 vaccination has been correlated with a decline in COVID-19 diagnosis, hospitalization, and post-hospital mortality.

As of March 2020, 3,677 out of 531,033 adults 65 years of age and older, who joined KPSC and were vaccinated by PCV13, were diagnosed with COVID-19, whereas